Skip to main content
. 2024 Jul 31;5(1):100590. doi: 10.1016/j.xops.2024.100590

Figure 5.

Figure 5

Subconjunctival ssAAV2-STC-1-FLAG lowers IOP in an equivalent manner to latanoprost. A, Graph showing IOPs of individual treatments over 4 weeks. B, Bar graph showing no significant difference in IOP between subconjunctival delivered ssAAV2-GFP (2μL; 6 × 109 VG) and fellow untreated control eye. Single-strand-AAV2-STC-1-FLAG (2μL; 6 × 109 VG), topical latanoprost (0.005%), topical LFA (10−4 M), and topical rhSTC-1 (5 μL; 0.5μg/μL) all showed a significant decrease in IOP compared with the fellow eye. No significant difference was seen between topical latanoprost, topical LFA, topical rhSTC-1, or ssAAV2-STC-1-FLAG. ∗∗P < 0.01. GFP = green fluorescent protein; IOP = intraocular pressure; LFA = latanoprost-free acid; rhSTC-1 = recombinant human stanniocalcin-1; ssAAV2-STC-1-FLAG = single-stranded, adeno-associated virus, serotype 2, engineered to express stanniocalcin-1 with a FLAG tag; STC-1 = stanniocalcin-1; VG = viral genome.